DVL2 and neoplasm: TRIM14 may promote the malignant progression of glioma through dual molecular mechanisms: on one hand, by upregulating Zinc Finger E-box Binding Homeobox 2 (ZEB2) expression to induce epithelial–mesenchymal transition (EMT), thereby enhancing tumor cell invasiveness; on the other hand, by stabilizing Disheveled Segment Polarity Protein 2 (Dvl2) protein to activate the Wnt/β-catenin signaling pathway, ultimately contributing to the development of chemoresistance [15].